Landis John B. 4
4 · EyePoint Pharmaceuticals, Inc. · Filed Feb 13, 2023
Insider Transaction Report
Form 4
Landis John B.
Director
Transactions
- Exercise/Conversion
Common Stock
2023-02-09+3,000→ 11,400 total - Exercise/Conversion
Restricted Stock Units
2023-02-09−3,000→ 0 totalExercise: $0.00→ Common Stock (3,000 underlying)
Footnotes (1)
- [F1]Fully vested on the one-year anniversary of the grant date.